BCL2 and B-cell chronic lymphocytic leukemia: First attempts with oblimersen (BCL2 antisense phosphorothioate oligodeoxynucleotide G3139) and Oblataclax (BH3 mimetic BCL2 inhibitor GX15-070) were not very successful in CLL [26].